STOK
insider transactionsStoke Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-93.6K
0 buy · 93.6K sell
Net value · 365d
-$3.4M
$0 in · $3.4M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
31
0 buy · 93.6K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
GENERAL COUNSEL & CORP SEC · 10b5-1
$43.6K
1.5K sh · $29.95
Own -7%
-
Grant·A
Director
$0
17.8K sh
Own New
-
Grant·A
Director
$0
17.8K sh
Own New
-
Grant·A
Director
$0
17.8K sh
Own New
-
Grant·A
Director
$0
17.8K sh
Own New
-
Grant·A
Director
$0
17.8K sh
Own New
-
Grant·A
Director
$0
17.8K sh
Own New
-
Grant·A
Director
$0
17.8K sh
Own New
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$54.9K
1.8K sh · $30.58
Own -5%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$73.5K
2.2K sh · $32.79
Own -6%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$60.0K
1.8K sh · $32.66
Own -5%
-
Sell·S
GENERAL COUNSEL & CORP SEC · 10b5-1
$20.7K
601 sh · $34.41
Own -3%
-
Sell·S
GENERAL COUNSEL & CORP SEC · 10b5-1
$292.4K
8.7K sh · $33.64
Own -30%
-
Exercise·M
CHIEF MEDICAL OFFICER · 10b5-1
$0
1.4K sh
Own +2%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$43.8K
1.5K sh · $29.99
Own -3%
-
Exercise·M
CHIEF MEDICAL OFFICER · 10b5-1
$3.0K
1.4K sh · $2.19
Own +3%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$3.4K
103 sh · $32.85
Own -0%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$15.4K
483 sh · $31.79
Own -1%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$190.8K
6.1K sh · $31.28
Own -13%
-
Sell·S
Thomas Leggett KEY
Chief Financial Officer
$1.2K
37 sh · $32.85
Own -0%
-
Sell·S
Thomas Leggett KEY
Chief Financial Officer
$5.5K
172 sh · $31.79
Own -2%
-
Sell·S
Thomas Leggett KEY
Chief Financial Officer
$68.0K
2.2K sh · $31.28
Own -17%
-
Sell·S
Chief Patient Officer
$986
30 sh · $32.85
Own -0%
-
Sell·S
Chief Patient Officer
$4.4K
139 sh · $31.79
Own -1%
-
Sell·S
Chief Patient Officer
$55.1K
1.8K sh · $31.28
Own -14%
-
Sell·S
GENERAL COUNSEL & CORP SEC
$2.4K
72 sh · $32.85
Own -0%
-
Sell·S
GENERAL COUNSEL & CORP SEC
$10.6K
334 sh · $31.79
Own -1%
-
Sell·S
GENERAL COUNSEL & CORP SEC
$132.1K
4.2K sh · $31.28
Own -13%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$86.3K
2.6K sh · $33.38
Own -5%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$117.1K
3.6K sh · $32.74
Own -7%
-
Sell·S
Thomas Leggett KEY
Chief Financial Officer
$30.8K
922 sh · $33.38
Own -7%
-
Sell·S
Thomas Leggett KEY
Chief Financial Officer
$41.7K
1.3K sh · $32.74
Own -9%
-
Sell·S
Chief Patient Officer
$25.0K
748 sh · $33.38
Own -6%
-
Sell·S
Chief Patient Officer
$33.8K
1.0K sh · $32.74
Own -7%
-
Sell·S
GENERAL COUNSEL & CORP SEC
$59.8K
1.8K sh · $33.38
Own -5%
-
Sell·S
GENERAL COUNSEL & CORP SEC
$81.1K
2.5K sh · $32.74
Own -7%
-
Exercise·M
CHIEF MEDICAL OFFICER
$0
10.8K sh
Own +50%
-
Exercise·M
CHIEF MEDICAL OFFICER
$0
10.0K sh
Own +100%
-
Exercise·M
CHIEF MEDICAL OFFICER
$0
13.1K sh
Own New
-
Exercise·M
CHIEF MEDICAL OFFICER
$0
10.8K sh
Own +25%
-
Exercise·M
CHIEF MEDICAL OFFICER
$0
10.0K sh
Own +30%
-
Exercise·M
CHIEF MEDICAL OFFICER
$0
13.1K sh
Own +66%
-
Exercise·M
Thomas Leggett KEY
Chief Financial Officer
$0
14.8K sh
Own +50%
-
Exercise·M
Thomas Leggett KEY
Chief Financial Officer
$0
14.8K sh
Own New
-
Exercise·M
Director
$0
26.2K sh
Own +100%
-
Exercise·M
Director
$0
35.5K sh
Own New
-
Exercise·M
Director
$0
26.2K sh
Own +31%
-
Exercise·M
Director
$0
35.5K sh
Own +72%
-
Exercise·M
Chief Patient Officer
$0
10.0K sh
Own +50%
-
Exercise·M
Chief Patient Officer
$0
10.0K sh
Own +251%
-
Exercise·M
GENERAL COUNSEL & CORP SEC
$0
12.0K sh
Own +50%
-
Exercise·M
GENERAL COUNSEL & CORP SEC
$0
6.0K sh
Own +100%
-
Exercise·M
GENERAL COUNSEL & CORP SEC
$0
7.5K sh
Own New
-
Exercise·M
GENERAL COUNSEL & CORP SEC
$0
12.0K sh
Own +47%
-
Exercise·M
GENERAL COUNSEL & CORP SEC
$0
6.0K sh
Own +30%
-
Exercise·M
GENERAL COUNSEL & CORP SEC
$0
7.5K sh
Own +61%
-
Sell·S
Director · 10b5-1
$22.3K
605 sh · $36.80
Own -12%
-
Exercise·M
Arthur Tzianabos KEY
Interim Executive Chair · 10b5-1
$0
4.0K sh
Own +3%
-
Sell·S
Arthur Tzianabos KEY
Interim Executive Chair · 10b5-1
$174.2K
4.4K sh · $40.00
Own -12%
-
Exercise·M
Arthur Tzianabos KEY
Interim Executive Chair · 10b5-1
$32.9K
4.0K sh · $8.33
Own +12%
-
Sell·S
Director · 10b5-1
$1.3M
33.2K sh · $39.74
Own -11%
-
Sell·S
Director · 10b5-1
$286.7K
7.2K sh · $39.66
Own -2%
-
Grant·A
CHIEF MEDICAL OFFICER
$0
40.0K sh
Own New
-
Grant·A
CHIEF MEDICAL OFFICER
$0
60.0K sh
Own New
-
Grant·A
Thomas Leggett KEY
Chief Financial Officer
$0
40.0K sh
Own New
-
Grant·A
Thomas Leggett KEY
Chief Financial Officer
$0
60.0K sh
Own New
-
Grant·A
Chief Patient Officer
$0
48.0K sh
Own New
-
Grant·A
Chief Patient Officer
$0
72.0K sh
Own New
-
Grant·A
GENERAL COUNSEL & CORP SEC
$0
35.0K sh
Own New
-
Grant·A
GENERAL COUNSEL & CORP SEC
$0
53.0K sh
Own New
-
Exercise·M
Director
$0
1.2K sh
Own New
-
Exercise·M
Director
$0
1.2K sh
Own +33%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Jonathan Allan 10b5-1 | Sell S | 1.5K | $43.6K |
| Jun 3, 2026 | Arthur Tzianabos | Grant A | 17.8K | $0 |
| Jun 3, 2026 | Julie Smith | Grant A | 17.8K | $0 |
| Jun 3, 2026 | LEVIN ARTHUR A | Grant A | 17.8K | $0 |
| Jun 3, 2026 | Adrian R. Krainer | Grant A | 17.8K | $0 |
| Jun 3, 2026 | Edward M. Kaye MD | Grant A | 17.8K | $0 |
| Jun 3, 2026 | Seth Loring Harrison | Grant A | 17.8K | $0 |
| Jun 3, 2026 | Jennifer Burstein | Grant A | 17.8K | $0 |
| Jun 1, 2026 | Barry Ticho 10b5-1 | Sell S | 1.8K | $54.9K |
| May 1, 2026 | Barry Ticho 10b5-1 | Sell S | 2.2K | $73.5K |
| Apr 1, 2026 | Barry Ticho 10b5-1 | Sell S | 1.8K | $60.0K |
| Mar 20, 2026 | Jonathan Allan 10b5-1 | Sell S | 601 | $20.7K |
| Mar 20, 2026 | Jonathan Allan 10b5-1 | Sell S | 8.7K | $292.4K |
| Mar 19, 2026 | Barry Ticho 10b5-1 | Exercise M | 1.4K | $0 |
| Mar 19, 2026 | Barry Ticho 10b5-1 | Sell S | 1.5K | $43.8K |
| Mar 19, 2026 | Barry Ticho 10b5-1 | Exercise M | 1.4K | $3.0K |
| Mar 18, 2026 | Barry Ticho 10b5-1 | Sell S | 103 | $3.4K |
| Mar 18, 2026 | Barry Ticho 10b5-1 | Sell S | 483 | $15.4K |
| Mar 18, 2026 | Barry Ticho 10b5-1 | Sell S | 6.1K | $190.8K |
| Mar 18, 2026 | Thomas Leggett KEY | Sell S | 37 | $1.2K |
| Mar 18, 2026 | Thomas Leggett KEY | Sell S | 172 | $5.5K |
| Mar 18, 2026 | Thomas Leggett KEY | Sell S | 2.2K | $68.0K |
| Mar 18, 2026 | Jason Hoitt | Sell S | 30 | $986 |
| Mar 18, 2026 | Jason Hoitt | Sell S | 139 | $4.4K |
| Mar 18, 2026 | Jason Hoitt | Sell S | 1.8K | $55.1K |
| Mar 18, 2026 | Jonathan Allan | Sell S | 72 | $2.4K |
| Mar 18, 2026 | Jonathan Allan | Sell S | 334 | $10.6K |
| Mar 18, 2026 | Jonathan Allan | Sell S | 4.2K | $132.1K |
| Mar 17, 2026 | Barry Ticho 10b5-1 | Sell S | 2.6K | $86.3K |
| Mar 17, 2026 | Barry Ticho 10b5-1 | Sell S | 3.6K | $117.1K |
| Mar 17, 2026 | Thomas Leggett KEY | Sell S | 922 | $30.8K |
| Mar 17, 2026 | Thomas Leggett KEY | Sell S | 1.3K | $41.7K |
| Mar 17, 2026 | Jason Hoitt | Sell S | 748 | $25.0K |
| Mar 17, 2026 | Jason Hoitt | Sell S | 1.0K | $33.8K |
| Mar 17, 2026 | Jonathan Allan | Sell S | 1.8K | $59.8K |
| Mar 17, 2026 | Jonathan Allan | Sell S | 2.5K | $81.1K |
| Mar 15, 2026 | Barry Ticho | Exercise M | 10.8K | $0 |
| Mar 15, 2026 | Barry Ticho | Exercise M | 10.0K | $0 |
| Mar 15, 2026 | Barry Ticho | Exercise M | 13.1K | $0 |
| Mar 15, 2026 | Barry Ticho | Exercise M | 10.8K | $0 |
| Mar 15, 2026 | Barry Ticho | Exercise M | 10.0K | $0 |
| Mar 15, 2026 | Barry Ticho | Exercise M | 13.1K | $0 |
| Mar 15, 2026 | Thomas Leggett KEY | Exercise M | 14.8K | $0 |
| Mar 15, 2026 | Thomas Leggett KEY | Exercise M | 14.8K | $0 |
| Mar 15, 2026 | Edward M. Kaye MD | Exercise M | 26.2K | $0 |
| Mar 15, 2026 | Edward M. Kaye MD | Exercise M | 35.5K | $0 |
| Mar 15, 2026 | Edward M. Kaye MD | Exercise M | 26.2K | $0 |
| Mar 15, 2026 | Edward M. Kaye MD | Exercise M | 35.5K | $0 |
| Mar 15, 2026 | Jason Hoitt | Exercise M | 10.0K | $0 |
| Mar 15, 2026 | Jason Hoitt | Exercise M | 10.0K | $0 |
| Mar 15, 2026 | Jonathan Allan | Exercise M | 12.0K | $0 |
| Mar 15, 2026 | Jonathan Allan | Exercise M | 6.0K | $0 |
| Mar 15, 2026 | Jonathan Allan | Exercise M | 7.5K | $0 |
| Mar 15, 2026 | Jonathan Allan | Exercise M | 12.0K | $0 |
| Mar 15, 2026 | Jonathan Allan | Exercise M | 6.0K | $0 |
| Mar 15, 2026 | Jonathan Allan | Exercise M | 7.5K | $0 |
| Mar 13, 2026 | LEVIN ARTHUR A 10b5-1 | Sell S | 605 | $22.3K |
| Mar 10, 2026 | Arthur Tzianabos KEY 10b5-1 | Exercise M | 4.0K | $0 |
| Mar 10, 2026 | Arthur Tzianabos KEY 10b5-1 | Sell S | 4.4K | $174.2K |
| Mar 10, 2026 | Arthur Tzianabos KEY 10b5-1 | Exercise M | 4.0K | $32.9K |
| Mar 10, 2026 | Adrian R. Krainer 10b5-1 | Sell S | 33.2K | $1.3M |
| Mar 2, 2026 | Adrian R. Krainer 10b5-1 | Sell S | 7.2K | $286.7K |
| Feb 17, 2026 | Barry Ticho | Grant A | 40.0K | $0 |
| Feb 17, 2026 | Barry Ticho | Grant A | 60.0K | $0 |
| Feb 17, 2026 | Thomas Leggett KEY | Grant A | 40.0K | $0 |
| Feb 17, 2026 | Thomas Leggett KEY | Grant A | 60.0K | $0 |
| Feb 17, 2026 | Jason Hoitt | Grant A | 48.0K | $0 |
| Feb 17, 2026 | Jason Hoitt | Grant A | 72.0K | $0 |
| Feb 17, 2026 | Jonathan Allan | Grant A | 35.0K | $0 |
| Feb 17, 2026 | Jonathan Allan | Grant A | 53.0K | $0 |
| Dec 31, 2025 | LEVIN ARTHUR A | Exercise M | 1.2K | $0 |
| Dec 31, 2025 | LEVIN ARTHUR A | Exercise M | 1.2K | $0 |
About STOK insider trading
This page tracks insider transactions for Stoke Therapeutics, Inc. (STOK) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.